We noticed that the NET production induced by plasma from severe COVID-19 patients could not be completely inhibited by either neutralizing antibodies or recombinant CPB (Fig. 3a), which implied that in addition to anaphylatoxins, there were other inducers of NETs in the plasma of severe patients. The gene discussed is CPB1; the disease is COVID-19.